We further confirmed dephosphorylation of FASN by lapatinib by measuring total and phosphorylated FASN levels in HER2-positive SKBR3 and BT474 breast cancer cells with or without treatment with a clinically relevant concentration of lapatinib [28] overnight (Additional file 1C). This evidence concerns the gene FASN and breast carcinoma.